We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated…
BOS (Biotech Outsourcing Strategies) Basel 2019 will bring together stakeholders in pharmaceutical R&D outsourcing, who share knowledge, develop skills and…
TherapeutAix will be at the EASL conference in Vienna, Austria, from the 10th – 14th April 2019. They will be…
At the end of last year, TherapeutAix published an article titled ‘The future R&D landscape in non-alcoholic steatohepatitis’ in Drug…
MassBio is holding a ‘State of Possible Conference’ for 2 days on the 27-28th March in Cambridge, Massachusetts. The event…